A

AdvanCell

Manufactures Lead-212 for targeted alpha therapy

Senior Scientist - Radiochemical Separations

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeBrisbane QLD, AustraliaNo salary listed

About the Job

Requirements

  • A Bachelor of Science, Master of Science, or PhD in Chemistry, Science, or a relevant field, with analytical or radiochemistry experience.
  • Demonstrated leadership experience managing, mentoring, and developing technical and scientific direct reports within a complex operational or research and development environment.
  • Ability to lead technical programs from early-stage development through scale-up, manufacturing implementation, and operational integration.
  • Sound understanding of Good Manufacturing Practice, quality systems, radiation safety, and regulated manufacturing environments.
  • Ability to influence and collaborate across cross-functional stakeholder groups, including Quality, Manufacturing, Safety, and Engineering.
  • Commercial and operational awareness, with the ability to balance scientific innovation with business priorities, timelines, and delivery requirements.
  • Experience managing complex technical problem-solving activities and driving continuous improvement initiatives.
  • Written and verbal communication skills, including the ability to communicate complex technical concepts clearly to technical and non-technical audiences.
  • Ability to operate effectively in a dynamic, high-growth environment with evolving priorities and competing demands.

Responsibilities

  • Lead the development, optimisation, and execution of radiochemical separation and purification processes for Th-228, including translation into scalable and automated processes.
  • Develop and implement gaseous Rn-220 handling and separation systems, and lead their optimisation and implementation in scaled Th-228 processes.
  • Provide scientific and technical leadership in designing and executing experiments to identify, characterise, and control critical process parameters that affect isotope yield, purity, and process robustness.
  • Support the development and implementation of chemical, radiochemical, and radionuclide characterisation methodologies.
  • Oversee generation, analysis, and trending of process development and manufacturing data for translation into routine production and continuous improvement.
  • Serve as the subject matter expert for radiochemical separation technologies transferred into routine production, providing technical oversight, troubleshooting support, and continuous process improvement.
  • Integrate into the Th-228 Radiochemical Processing team and support routine high-activity radiochemical processing operations, including integration with existing Th-228 processing workflows.
  • Author, review, and maintain standard operating procedures, technical reports, protocols, and other manufacturing documentation as required.
  • Lead, mentor, and develop members of the Radiochemical Separations team, fostering a performance-focused, collaborative, and safety-focused culture aligned with organisational values and objectives.
  • Collaborate within the Technology Development and Innovation Function and with other company functions to identify opportunities for process improvement.
  • Work closely with the Radiation Safety Officer to ensure compliance with the radiation safety program and site radioactive material licence.
  • Provide technical support and radiochemical expertise to other teams or business units as required to support broader organisational objectives.
  • Participate in day-to-day laboratory maintenance.
  • Observe the employer’s workplace, health and safety, and regulatory policies.

Desired Qualifications

  • Experience with radionuclide development and/or production.
  • Experience with separations, solid-phase extraction technologies, and process automation.
  • Experience with high-purity germanium spectrometry, inductively coupled plasma mass spectrometry, or similar analytical methodologies.
  • Experience working with alpha-, beta-, and gamma-emitting radionuclides.

About the Company

AdvanCell

Manufactures Lead-212 for targeted alpha therapy

AdvanCell develops radiopharmaceuticals for targeted alpha therapy, using Lead-212 and an on-demand Alpha Isotope Generator to produce the isotope daily. Its core product ADVC-001 targets PSMA to treat metastatic castration-resistant prostate cancer, evaluated in the multicenter TheraPb Phase I/II trial, while the company also pipelines other cancer therapies. The approach combines isotope production, drug manufacturing, and clinical development in a vertically integrated model to ensure reliable supply and faster development. Its goal is to speed patient access to radiopharmaceutical treatments by expanding its portfolio through collaborations, including a strategic partnership with Eli Lilly, and advancing clinical trials.

Company size
51-200
Company stage
Series D
Total funding
$440.8M
Headquarters
Sydney NSW, Australia
Founded
2019

Recently Posted Jobs

Explore more opportunities at AdvanCell

See more jobs